scholarly journals Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome

2015 ◽  
Vol 21 (40) ◽  
pp. 11379 ◽  
Author(s):  
Hamish Philpott
2010 ◽  
Vol 53 (2) ◽  
pp. 156-160 ◽  
Author(s):  
V P. Suttor ◽  
G M. Prott ◽  
R D. Hansen ◽  
J E. Kellow ◽  
A Malcolm

2015 ◽  
Vol 41 (5) ◽  
pp. 438-448 ◽  
Author(s):  
M. Camilleri ◽  
A. Acosta ◽  
I. Busciglio ◽  
A. Boldingh ◽  
R. B. Dyer ◽  
...  

2018 ◽  
Vol 1 (1) ◽  
Author(s):  
Chirag Patel ◽  
Carolyn Lockett ◽  
Huiping Xu ◽  
Andrea Shin

Background and Aims: Fecal bile acids (BAs), short chain fatty acids (SCFAs), and gut microbiome may be implicated in irritable bowel syndrome (IBS) pathophysiology. Our aim was to compare fecal organic acids between IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and controls.   Methods: Stool samples were collected from 17 controls, 5 IBS-C, and 5 IBS-D volunteers during a 4-day high fat diet. Aliquots were stored for future analysis of the fecal microbiota. Fecal SCFA and BA analyses were conducted at the Metabolite Profiling Facility at Purdue University and Laboratory Medicine and Pathology at Mayo Clinic. We compared SCFA and BA levels among groups using the Wilcoxon rank sum test. Gamma and linear regression were used to compare SCFAs and BAs adjusting for age and body mass index (BMI).  Results: Fecal acetate levels (mean+SD, µg/mg) were higher in IBS-C (11.3±7) than in controls (6.1±3.3) or IBS-D (7.7±2), although not statistically significant (p=0.19). Total fecal BAs (median [IQR], %) were higher in IBS-D (675 [484-778]) than in controls (342 [130-640]) or IBS-C (321.5 (34.5-718); however, differences were not significant. No significant differences were observed in BAs or SCFAs between groups in multivariate analyses.  Conclusion: We are unable to show significant differences in organic acid levels in IBS and controls. Lack of association may be due to small sample size. Future investigation of larger patient numbers with incorporation of transit and microbiome analyses may shed further light on the role of organic acids in IBS to identify new biomarkers and treatment targets.


2015 ◽  
Vol 43 (03) ◽  
pp. 385-406 ◽  
Author(s):  
Chun-Yan Li ◽  
Nurul Ain Mohd Tahir ◽  
Shu-Chuen Li

Traditional Chinese medicine (TCM) has been commonly used by Chinese practitioners to treat irritable bowel syndrome (IBS). However, the effectiveness of combining TCM with Western medicine in managing IBS has not been evaluated systematically. In this study, we evaluated the clinical effectiveness of combining TCM and Western medicine in the treatment of IBS via meta-analyses. We reviewed 72 eligible randomized controlled trials from January 2009 to December 2013 investigating the effectiveness of integrated TCM and Western medicine in the management of IBS. In the meta-analyses, the relative risks (RRs) and 95% confidence interval (95%CI) were calculated using raw data from each study, and low heterogeneity was detected. When compared to the Western medicine treatment alone, our result showed TCM combined with Western interventions significantly improved IBS global symptoms (RR, 1.21; 95%CI: 1.18–1.24). Additionally, there was no significant difference in therapeutic effects of the integrated approach in the meta-analyses involving the various IBS subtypes. Likewise, both Chinese proprietary herbal medicine plus conventional treatment and compound herbal preparations plus conventional treatment showed similar and statistically significant effects on global improvement compared with western treatment alone, with RRs of 1.22 (95%CI: 1.14–1.30) and 1.22 (95%CI: 1.18–1.27), respectively. These results demonstrated that treating IBS with integrated traditional Chinese and Western medicines showed better effectiveness than conventional Western medicine alone. Although due to the quality of the included studies, our results might possess a high risk of bias. TCM, particularly Chinese proprietary medicine, with the benefits of low-cost, easy to use, and good palatability, would be an attractive option to be used in conjunction with conventional Western medicine to manage IBS patients.


2013 ◽  
Vol 11 (10) ◽  
pp. 1270-1275.e1 ◽  
Author(s):  
Andrea Shin ◽  
Michael Camilleri ◽  
Priya Vijayvargiya ◽  
Irene Busciglio ◽  
Duane Burton ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document